Last reviewed 2026-04-19 · How we verify

ETOXADROL

Phase 2 active Small molecule

ETOXADROL is a drug. It is currently in Phase 2 development.

ETOXADROL works by binding to specific biological molecules to produce a therapeutic effect.

ETOXADROL is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. However, without more information, it is difficult to provide a comprehensive summary of its mechanism of action and safety considerations. Further research is needed to fully understand ETOXADROL's properties and potential uses.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETOXADROL
Target	Glutamate NMDA receptor
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine ETOXADROL as a key that fits into a lock on a specific protein in the body. When it binds to this protein, it can either block or enhance the protein's activity, leading to changes in the body's chemistry that can help treat a particular disease or condition. This is a simplified explanation of how small molecule drugs like ETOXADROL work.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ETOXADROL CI brief — competitive landscape report
ETOXADROL updates RSS · CI watch RSS

Frequently asked questions about ETOXADROL

What is ETOXADROL?

ETOXADROL is a Small molecule drug.

How does ETOXADROL work?

ETOXADROL works by binding to specific biological molecules to produce a therapeutic effect.

What development phase is ETOXADROL in?

ETOXADROL is in Phase 2.

What does ETOXADROL target?

ETOXADROL targets Glutamate NMDA receptor.

Target: All drugs targeting Glutamate NMDA receptor
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing